Skip to main content

Table 2 Summary of efficacy

From: Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial

Responder rate, % (95% CI)

OMERACT-OARSIResponder

Controlled Responder

PGA responder

Week 2

66.0 (58.2–73.7)

54.2 (46.0–62.3)

66.0 (58.2–73.7)

Week 6

66.0 (58.2–73.7)

58.3 (50.3–66.4)

61.8 (53.9–69.7)

Week 10

72.2 (64.9–79.5)

61.8 (53.9–69.7)

72.9 (65.7–80.2)

Week 12

70.8 (63.4–78.3)

64.6 (56.8–72.4)

66.0 (58.2–73.7)

  1. CI confidence interval, OMERACT-OARSI Outcome Measures in Rheumatology (OMERACT) - Osteoarthritis Research Society International (OARSI), PGA Patient Global
  2. Assessment. Efficacy endpoints were analyzed with one-sided exact binomial test compared to null hypothesis of 30% responder rate. P < 0.001 for all responder rates at all time points